Acquired peripheral neuropathy: a report on 20 children.
Guillain-Barré syndrome (GBS) is an inflammatory polyneuropathy characterized by acute onset, rapid progression, symmetric muscular weakness, pain, and paresthesias. The incidence of GBS in the pediatric age group is 0.8 cases per 100,000; 50%-70% of the cases are preceded by respiratory or gastrointestinal infectious episodes or vaccination. The etiopathogenesis of GBS has been hypothesized to involve a direct immune-mediated mechanism against the peripheral nerves. A series of 20 patients managed in the Department of Pediatrics of the University of Catania between 2003 and 2011 and evaluated according to epidemiologic, clinical, and therapeutic features is reported.
P
P
Pavone
A D
AD
Praticò
M
M
Ruggieri
A
A
Verrotti
D
D
Castellano-Chiodo
F
F
Greco
R
R
Falsaperla
L
L
Pavone
D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D001323:Autoantibodies / Q000097:blood / Q000134:cerebrospinal fluid; D015415:Biomarkers / Q000134:cerebrospinal fluid; D002648:Child; D002675:Child, Preschool; D004185:Disability Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005732:Gangliosides / Q000276:immunology; D020275:Guillain-Barre Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007558:Italy; D008297:Male; D009460:Neurologic Examination; D011237:Predictive Value of Tests; D012008:Recurrence; D012189:Retrospective Studies; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents; D001323:Autoantibodies; D015415:Biomarkers; D005732:Gangliosides; D016756:Immunoglobulins, Intravenous; D013256:Steroids